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Highlights 
 
• Novel chymotrypsin-like activity implicated in the maintenance of cell 
viability 
• Inhibition by TMR-PheP(OPh)2 caused a decrease in HeLa and U251 cell 
viability 
• Reduced viability was associated with an increase in caspase-3 activity over 
time 
• PARP cleavage and phosphatidylserine translocation were also observed 
• Inhibition of this protease initiates a cascade of apoptotic-related events 
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Abstract 
An increasing number of studies have implicated serine proteinases in the 
development of apoptosis. In this study, we assessed the ability of a set of highly 
specific irreversible inhibitors (activity probes), incorporating an α-amino alkane 
diphenyl phosphonate moiety, to modulate cell death. In an initial assessment of the 
cellular toxicity of these activity probes, we discovered that one example, N-
α−tetramethylrhodamine phenylalanine diphenylphosphonate {TMR-PheP(OPh)2} 
caused a concentration-dependent decrease in the viability of HeLa and U251 mg 
cells.  This reduced cell viability was associated with a time-dependent increase in 
caspase-3 activity, PARP cleavage and phosphatidylserine translocation, establishing 
apoptosis as the mechanism of cell death. SDS-PAGE analysis of cell lysates prepared 
from the HeLa cells treated with TMR-PheP(OPh)2, revealed the presence of a 
fluorescent band of molecular weight 58kDa. Given that we have previously reported 
on the use of this type of activity probe to reveal active proteolytic species, we believe 
that we have identified a chymotrypsin-like serine proteinase activity integral to the 
maintenance of cell viability.   
 
Keywords: Chymotrypsin, proteinases, apoptosis, serine, inhibitor, 
diphenylphosphonate 
 
Abbreviations: PARP – Poly (ADP-ribose) polymerase, PS – phosphatidylserine, 
TMR-PheP(OPh)2 – N-α-tetramethylrhodamine phenylalanine diphenylphosphonate; 
TLCK - N-α-tosyl-L-lysine chloromethyl ketone , TPCK - N-α-tosyl-L-phenylalanine 
chloromethyl ketone,    
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1. Introduction 
Proteolytic cleavage of intracellular proteins is a core feature of apoptosis. In this 
regard, the role of the caspase family of cysteine proteinases has been well-
established; however, increasing attention is now being paid to the potential roles of 
other protease classes and families in this process. The involvement of serine 
proteinases in apoptosis was suggested as early as 1987 [1] and by 1994, a further 
association was established when it was demonstrated that the introduction of 
chymotrypsin and trypsin into tumour cells led to a form of cell death indicative of 
apoptosis [2]. Other studies have focussed on attempts to identify and describe the 
actual role and function of serine proteases within apoptotic processing [3-7] 
however; the specific proteinases involved remain elusive and unidentified. 
Chymotrypsin-like proteases have however, emerged as prime candidates for further 
study [8-11]. 
Due to the diversity and quantity of proteases involved in apoptosis, experimental 
tools in the identification of unknown proteases within model systems have centred on 
the utilisation of protease inhibitors which facilitates the indirect study of apoptotic 
effects through the modulation or augmentation of particular apoptotic events. 
Protease-inhibitor binding alone however, does not impart information about the 
location, quantity or subcellular identification of target proteases. In addition, 
classification of an enzyme as belonging to the serine proteinase class on the basis of 
inhibition by N-Tosyl-Phenylalanine chloromethyl ketone (TPCK) and N-Tosyl-
Lysine chloromethyl ketone (TLCK) should be treated with circumspection, as these 
compounds are not uniquely diagnostic for the action of this mechanistic class [12-
14]. 
In contrast, Powers and coworkers have pioneered the development of potent and 
peptide derivatives of diphenyl [1-(N-peptidylamino)alkyl] phosphonate esters that 
act as exquisitely selective, irreversible inactivators of the serine proteases [15-17]. 
This group utilized biotinylated and fluorescently labelled derivatives to detect a 
range of serine proteolytic activities, including lymphocyte serine proteases 
(granzymes) [18-19]. We have also reported on the application of such phosphonate-
based inhibitors for the detection of trypsin-like and chymotrypsin-like serine 
proteases [20-22] and, more recently, on the development of an active site-directed 
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probe for dipeptidyl peptidase IV-like serine proteases, based on a biotinylated 
dipeptide proline diphenylphosphonate [23-24].  
Active site-directed inhibitors consisting of a warhead, a specific amino acid sequence 
and a reporter group (e.g. biotin) are essential tools in the application of the detection 
and characterisation of proteolytic activities in various biological systems [20, 25, 26]. 
In addition to biotinylated affinity labelling, the use of fluorogenic labels has been 
developed as another primary method of proteinase visualisation [22, 27]. This latter 
approach in particular, accommodates confocal and fluorescent microscopy as well as 
flow and laser cytometry, resulting in enhanced imaging and measurements of 
intracellular activity [28].  
Based on the emerging research implicating serine proteases within apoptotic 
pathways, we investigated the presence of novel serine proteases utilising a 
combination library of ‘in-house’ and commercially available inhibitors. This 
approach has recently been adopted by other research groups [29].   The majority of 
‘in-house’ inhibitors utilised in our study were based on the diphenyl phosphonate 
war-head. Diphenyl phosphonate groups are specific and potent irreversible inhibitors 
of serine proteases [15, 30] reacting covalently with the active site serine, thus 
affording a phosphonylated and irreversibly inhibited enzyme [16-17]. Diphenyl 
phosphonates are advantageous over other synthetic serine protease inhibitors as they 
show no activity against cysteine proteases, are non-toxic in vivo and are 
exceptionally stable under physiological conditions [15, 31-32]. Utilising the specific 
affinity probe TMR-PheP(OPh)2, we report the detection of a novel chymotrypsin-like 
serine proteinase, inhibition of which initiates caspase-mediated cell death in vitro.  
We therefore, postulate a critical role for this enzyme in the maintenance of cell 
viability, although the identification of the protein substrate has yet to be determined.  
   
2. Material and Methods 
2.1 Cell culture and reagents: HeLa cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Wiltshire, UK) and cultured in 
Eagles Minimum Essential Medium (EMEM) (Sigma-Aldrich Co. Ltd, Irvine, 
UK) supplemented with L-Glutamine (2 mM), Penicillin (10,000 units/ml) / 
Streptomycin (10,000 µg/ml streptomycin sulphate in 0.85% saline) and 10% 
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(v/v) Foetal Calf Serum (FCS) (Biowest, UK). The U251 mg cell line (American 
Type Culture Collection, Rockville, MD) was derived from a human glioblastoma 
multiforme. The cell line was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20 mmol/L glutamine and 10% (v/v) foetal calf 
serum (FCS). With the exception of EMEM and FCS, all cell culture media and 
reagents were purchased from Gibco BRL, Paisley, Scotland. 
2.2 Inhibitor/affinity probe synthesis:  The labelled diphenylphosphonate derivatives 
of phenylalanine were synthesised within the Biomolecular Sciences group, 
School of Pharmacy, Queen’s University, as previously described [22] utilising a 
modification of the method of Oleksyszen et al. [15]. N-α-tosyl-L-phenylalanine 
chloromethylketone (TPCK) and the cell-permeable caspase-3 inhibitor, Biotin-
DEVD-FMK were purchased from Sigma Chemical Company, Poole, England. 
2.3 Cell viability studies: Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer’s 
instructions (Sigma Chemical Company, Poole, England). In brief, cells were 
seeded onto a sterile 96-well cell culture plate at a concentration of 1 x 105 and 
incubated overnight at 37oC.  After 24 hours media was aspirated from cells and 
100 µl fresh media containing the peptide treatments added. Cells were further 
incubated at 37oC for the appropriate time period, followed by the addition of 
MTT (10 µl of a 10 mg/ml aqueous solution). Solubilisation of the resultant 
formazan crystals was through the addition of dimethyl sulphoxide (DMSO) and 
colour intensity was measured quantitatively at 550 nm on a Tecan Spectra 
Thermo plate reader from Tecan (Austria).  
2.4 Enzymatic activity assays: Following incubation with 100 µM 
Tetramethylrhodamine labelled-PheP(OPh)2 (henceforth known as TMR-Phe-
DPP), cells were harvested and disrupted using lysis buffer (0.1% (v/v) Triton X-
100 in sterile PBS). Caspase-3 and chymotrypsin-like activity were measured in 
lysates (25 µg protein/100 µl assay) utilising a standard microplate assay under the 
following conditions: Caspase-3; 50 mM HEPES, 100 mM NaCl, 0.1% (w/v) 
CHAPS, 10 mM DTT, 10% (w/v) sucrose containing Ac-DEVD-AMC 
(Calbiochem, CA, USA) (final concentration 25 µM) and for chymotrypsin-like 
activity; 50 mM sodium phosphate buffer (pH 7.4) containing N-Succinyl-Ala-
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Ala-Pro-Phe-AMC (Sigma-Aldrich, St. Louis, USA) (final concentration 50 µM).  
The rate of substrate hydrolysis was monitored every 60 s over a period of 1 hr 
using a FLUOstar OPTIMA (BMG Labtech) (λex 380 nm and λem 460 nm). 
2.5 PARP cleavage Assays:  Following treatment, cells were harvested and lysed as 
described in 2.4.  Lysates were reduced and denatured prior to electrophoresis by 
incubation with Laemmli treatment buffer at 100oC for 10 minutes. Equal amounts 
of protein (25 µg), were subjected to SDS-PAGE before being electroblotted onto 
a nitrocellulose membrane.  Non-specific binding sites were blocked by overnight 
incubation at 4oC with PBS containing 0.1% (v/v) Tween-20 (PBST) and 3% 
(w/v) BSA. Immunodetection was performed using a PARP monoclonal antibody 
(1:500 dilution; BD Pharmingen, San Diego, USA) in PBST containing 1% (w/v) 
BSA followed by washing in PBST containing 1% BSA (w/v) and incubation 
with a secondary peroxidase-coupled goat anti-mouse antibody (1:10000 dilution; 
BioRad, Herts, UK) under the same conditions. Blots were developed using the 
Supersignal West Pico Chemiluminescence system (Pierce, Rockford, Il, USA). 
2.6 Phosphatidylserine translocation and nucleic acid staining:  HeLa cells (1 x 105) 
were seeded onto a sterile 96-well cell culture plate and incubated overnight at 
37oC to allow for detachment.  At appropriate timepoints, media was aspirated 
from cells and 100 µl fresh media containing the peptide treatments added. 
Staining of phosphatidylserine translocation was undertaken using Annexin V-
Cy5 Apoptosis Detection Kit according to the manufacturer’s instructions 
(Biovision, CA, USA). Simultaneously, cells were stained with SYTOX® Green 
Nucleic Acid Stain according to the manufacturer’s protocol (Molecular Probes, 
U.S.A.).   Visualisation and imaging of cells was undertaken using an ECLIPSE 
TE300 inverted microscope with a TE-FM Epi-Fluorescence attachment and 
DXM1200 digital still camera (Nikon). 
2.7 Confocal imaging of cells:  U251 mg or HeLa cells were seeded at a 
concentration of 2 x 105 ml-1 onto a 22 mm x 22 mm coverslip within a 6 well 
sterile cell culture plate and incubated at 37oC overnight to aid attachment. Media 
was aspirated, and cells washed twice in sterile PBS. Media (3 ml) containing 
various concentrations of TMR-Phe-DPP (100 µM, 10 µM, 1 µM and 100 nM) 
was added and cells reincubated for 1 hour. Media containing peptide treatments 
were subsequently removed and cells washed with sterile PBS to remove residual 
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staining of the fluorophore. Coverslips were mounted onto microscope slides 
using mounting media and images taken using a Leica TCS SP2 Confocal 
microscope.  
2.8 Visualisation of protease target by SDS-PAGE:  HeLa cells were incubated at 
37oC, 5% CO2 for 24 hours with 100 µM TMR-Phe-DPP and 100 µM BPS-Phe-
DPP.  Cells were lysed in PBS, containing 0.1% (v/v) Triton X-100) and subjected 
to SDS-PAGE as mentioned previously. As an alternative, HeLa cells were 
incubated for 30 min with 100 µM Bio-Phe-DPP, TMR-Phe-DPP and Z-Phe-DPP.  
Cells were then lysed as before and the lysate subjected to a secondary incubation 
with 100 µM Biotin-Phe-DPP. The samples were then subjected to SDS-PAGE 
and Western Blotting with visualisation using streptavidin-horseradish peroxidase 
(1:5000) and chemiluminescence as before. 
2.9 Statistical analysis:  Data was analysed were appropriate using the Mann-Whitney 
U test of significance. 
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3. Results and Discussion 
3.1 Cell viability studies  
In our initial studies we assessed the effect of an extensive library of synthetic serine 
proteinase inhibitors on the viability of HeLa cells. These included inhibitors directed 
against elastase-like, trypsin-like and chymotrypsin-like proteases. This screen was 
carried out using 100 µM of each inhibitor with an exposure time of 24 hours. Of the 
inhibitors tested, only the chymotrypsin-directed inhibitors exhibited consistent and 
significant effects on viability (Table 1). Two of the phenylalanine diphenyl 
phosphonate derivatives possessed the fluorescent labels EDANS and TMR, whilst 
another was biotinylated (BPS-Phe-DPP). Inclusion of a tosyl-labelled phenylalanyl 
diphenyl phosphonate was to enable direct comparisons to be made with the 
traditionally used, commercially available TPCK. With the exception of the 
biotinylated inhibitor (BPS-Phe-DPP), each of the diphenyl phosphonates tested 
caused a significant reduction in cell viability of at least 30%, with the 
tetramethylrhodamine derivative exhibiting the most pronounced loss. It is postulated 
that the biotinylated inhibitor, which also possesses a PEG-succinyl-linker group, 
could have been too hydrophilic to cross the plasma-membrane. The commercially 
available chloromethylketone inhibitors, TPCK and TLCK have traditionally been 
utilised as ‘diagnostic tools’ to establish the action of serine proteinases.  In this study, 
we compared the effect of TPCK with its exactly analogous diphenyl phosphonate, 
Tosyl-Phe-DPP. We found that the former caused a 20% loss in cell viability 
compared to a near 30% decrease brought about by the latter. 
TPCK, originally designed as an irreversible inhibitor of chymotrypsin has however, 
been found to impact on apoptosis in a variety of ways which may not be due to its 
inhibition of serine proteases e.g. TPCK causes the release of pro-apoptotic factors 
from the mitochondria, can act as efficient direct inhibitors of mature caspases and 
may interfere with the cell cycle [33, 34].  Activation of apoptosis by TPCK also 
appears to be dependent upon whether apoptotic stimulation is present [33-35]. We 
found that when co-incubated with staurosporine, an apoptotic inducer, TPCK had a 
protective effect on HeLa cell viability (data not shown), which is in agreement 
O’Connell et al [36] and King et al [33]. However, in the absence of staurosporine 
TPCK induced a loss of viability. The wide range of biochemical and cellular effects 
displayed by chloromethyketones, including their direct inhibition of mature caspases 
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[34] indicates that the diphenylphosphonate-based inhibitors may be more selective 
tools to elucidate the role of serine proteases in apoptosis. 
TMR-Phe-DPP was found to exert a dose-dependent reduction in the viability of 
HeLa cells when studied over a range of 24 hr periods up to 96 hrs, with significant 
effects apparent at concentrations of 25 µM and above. To discount possible 
cytotoxicity due to compound-related differences (such as the inclusion of the TMR 
fluorophore) as a possible cause of cell death, we also carried out a dose response 
curve in HeLa cells with the TMR fluorophore alone for time periods of 24-96 hours. 
No discernible cytotoxic effects were observed in these studies (data not shown). The 
relative sensitivity of HeLa to TMR-Phe-DPP (100 µM) over time indicated a loss of 
viability within 4 hours of treatment (5%), increasing to 61% at 12 hours followed by 
a rapid loss of viability between 12 and 24 hours with only 9% of cells remaining.  In 
comparison, U251 mg cells demonstrated a high level of resilience to loss of viability 
in the early time-points, with 94% of cells still viable at 12 hours. By 18 hours 64% of 
cells remained viable. A rapid decline then ensued and by 24 hours viability was 12%, 
a figure comparable with that observed with HeLa cells. This data suggests that 
incubation with 100 µM TMR-Phe-DPP has a negative impact on the viability of both 
HeLa and U251 mg cells. To clarify that TMR-Phe-DPP was targeting a 
chymotrypsin-like protease, HeLa cells were incubated with 100 µM of the inhibitor 
for various time-points. Cells were harvested and lysed before being assayed 
fluorogenically for chymotrypsin-like activity (Figure 1). No significant differences 
were found between control and treated cells at early time-points however, a 
significant reduction in intracellular activity was observed at 4 and 6 hours with p-
values of 0.0183 and 0.0487 respectively. At 12 hours the differences were highly 
significant (***; p < 0.001).  Intra-plate variation may have impacted on a loss of 
significance at some of the other time-points.  
3.2 Analysis of caspase-3 activity 
Detection and measurement of activated caspase-3 is one of the classic benchmarks 
for confirming that apoptosis has been activated in cells [37].  Caspase activation 
initiates the irreversible state of apoptosis, hence detection of this event is often 
critical and a variety of approaches have been developed towards this aim [28]. 
Detection methods can be direct, for example immunodetection utilising a specific 
caspase-3 antibody or indirect through substrate-based activity assays.  
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Caspase-3 activity assays were performed on cell lysates prepared from HeLa and 
U251 mg cells exposed to 100 µM TMR-Phe-DPP for periods of up to 12 hours. 
Activity was monitored using the fluorogenic substrate Ac-DEVD-AMC. An increase 
in active caspase-3 levels over time, caused by the exposure of HeLa and U251 mg 
cells to TMR-Phe-DPP, is shown in Figures 2A and B, respectively. TMR-Phe-DPP 
was observed to induce a significant activation of caspase-3 after 4-6 hours of 
exposure. By 24 hours, levels of the protease increased 3.5-fold in the HeLa cells (p < 
0.05) and 10-fold in the U251 mg cells (p < 0.001) compared to the no treatment 
control.  The levels and timeliness of caspase-3 activation correlated appropriately 
with the loss of viability observed in both cell lines upon treatment with TMR-Phe-
DPP.  
To further ascertain that the loss of viability induced by TMR-Phe-DPP was caspase-3 
dependent and therefore associated with apoptosis, cells were pre-incubated for 4 
hours with 10 µM of the cell-permeable caspase-3 inhibitor Biotin-DEVD-FMK, 
followed by incubation with the TMR-labelled peptide as before. Cell viability was 
measured using the MTT assay.  Pre-incubation with the caspase-3 inhibitor served 
only to stall the initiation of apoptosis. From 18 hours, cell viability was reduced by 
over 90% both in the presence and absence of Biotin-DEVD-FMK.  
3.3 PARP cleavage Assays 
Caspase-3 cleavage of the nuclear repair enzyme poly (ADP-ribose) polymerase 
(PARP) is considered a very sensitive marker of caspase activation and apoptosis [38-
39]. In non-apoptotic cells PARP is observed in the uncleaved form (116 kDa), 
whereas in apoptotic cells PARP is characteristically cleaved to an indicator apoptotic 
fragment (85 kDa). To provide further confirmation that the loss of cell viability was 
due to apoptosis, cells were incubated with 100 µM TMR-Phe-DPP for a period of 30 
minutes to 24 hrs. In both HeLa and U251 mg cell lines, a residual amount of PARP 
cleavage was observed, however this is proposed to be due to normal housekeeping 
duties and no observable differences between control and treated cells were detected 
between 30 minutes and 8 hours. For HeLa cells following 12 hour post-treatment 
with TMR-Phe-DPP there was, however, a total depletion of the 116 kDa species, and 
only the 85 kDa form was visible (Figure 3A). In contrast, lysates prepared from 
U251 mg cells, which showed a delayed reduction in viability when treated with the 
diphenyl phosphonate inhibitor, revealed significant levels of the higher molecular 
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weight form of PARP in addition to the processed 85 kDa species at 12, 18 and 24 
hours post treatment times (Figure 3B).   
3.4 Phosphatidylserine Translocation 
Annexin V is a small Ca2+-dependent protein with high affinity for phosphatidylserine 
(PS) [40]. In normal living cells, PS is located in the inner layer of the cell membrane 
only, but in apoptotic cells this phospholipid is translocated to the outer leaflet. Once 
on the cell surface, PS can be easily detected by staining with a fluorescent conjugate 
of Annexin V and detection analysed by flow cytometry or fluorescent microscopy. 
To observe whether TMR-Phe-DPP would induce this translocation, HeLa cells were 
grown on coverslips and incubated with 100 µM of the inhibitor for various time-
periods. Using the Annexin-V-Cy5 staining kit, visualisation of PS was obtained 
using confocal microscopy (Figure 4).  Translocation of PS was observable at 3 hours 
with diffuse staining clearly visible at 4 and 6 hours.  In conjunction with annexin-V 
staining, Sytox Green, a nucleic acid stain, was used to observe necrotic and late 
apoptotic cells, based on the principle that nucleic acid stains easily penetrate cells 
with compromised plasma membranes.  There was no marked increase in Sytox green 
stained cells between the treated group and the control, indicating that the cell death 
observed was due to apoptosis and not necrosis (data not shown).   
3.5 Transport and uptake of TMR-Phe-DPP into cells 
Previous results based on cell viability and caspase-3 activation suggested that TMR-
Phe-DPP is cell-permeable. Studies were undertaken to observe the time-course of 
this inhibitor in relation to transmembrane delivery and subsequent morphological 
cellular changes. In addition to observing its intracellular location, it was important to 
understand the mechanism by which it enters cells.  
The microscopy images of HeLa cells showed that the inhibitor started to concentrate 
intracellularly within 30 minutes (Figure 5). By 4 hours post incubation 
morphological changes relating to apoptosis were observed, in particular the rounding 
up of cells. By 8 hours, blebbing of the plasma membrane alongside increased 
‘rounding up’ of cells was apparent indicative of apoptotic morphological changes.   
Confocal imaging of U251mg cells after treatment with TMR-Phe-DPP (100 µM) 
clearly showed a concentration of fluorescence within the cytosol with potential 
vesicle involvement (Figure 6A and B). This was further apparent at a peptide 
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concentration of 1 µM which highlighted the efficiency of transport and localisation 
of this inhibitor (Figure 6C). 
3.6 Identification of Molecular Weight of the Protease Target of TMR-Phe-DPP 
It is clear that TMR-Phe-DPP when incubated with cells induces loss of viability 
through the initiation of a cascade of apoptotic events.  The target protease may 
therefore have a critical role to play in the maintenance of cell viability and could 
have great potential as a target for anti-cancer therapies. To ascertain the molecular 
weight of its target protease, HeLa cells which had been treated with TMR-Phe-DPP 
were lysed and subjected to SDS-PAGE. A single fluorescent band of 58 kDa was 
detected under UV (Figure 7A). This species was also detected in cell lysates using 
BPS-Phe-DPP with the band markedly reduced/absent in cell preparations which had 
been pre-incubated with TMR-Phe-DPP and Z-Phe-DPP, respectively prior to lysis 
(Figure 7B). This confirmed the target of these inhibitors, regardless of 
protecting/reporter group, to be a chymotrypsin-like protease and highlights the 
relative cell permeability of these compounds.  
4. Conclusion 
A core feature of apoptosis is the proteolytic cleavage of intracellular proteins [41]. 
The proteases involved and the role they play will be variable and dependent upon 
both the origin of apoptotic stimuli and the cell type involved [42]. Once the process 
of apoptosis is initiated cells undergo a series of morphological and biochemical 
changes including membrane blebbing, caspase-3 activation, phosphatidylserine 
translocation and PARP cleavage [43]. Our initial investigations established that a 
chymotrypsin-like activity had a protective role in cell viability, as inhibition led to 
cell death within 24 hours. One inhibitor in particular, the fluorescently labelled 
TMR-Phe-DPP, had a profound effect on cell death. In light of much published 
research into the role of serine proteases in apoptosis, proof that the observed cell 
death was apoptosis and not necrosis was paramount. Further biochemical 
investigations using this very effective inhibitor confirmed an apoptotic mechanism of 
cell death as in addition to a time-dependent increase in caspase-3 activity; cleavage 
of the DNA repair enzyme PARP and translocation of phosphatidylserine to the outer 
leaflet of the plasma membrane were observed. Exclusion of sytox green, a nucleic 
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acid stain also confirmed that the observed cell death was apoptotic and not due to 
necrosis.   
These results highlight the importance of chymotrypsin-like serine proteases in the 
maintenance of cell viability. 
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Figure Legends 
 
Figure 1.  HeLa cells were incubated with 100 µM TMR-Phe-DPP, for various 
timepoints before being harvested and lysed in sterile PBS containing 0.1% TX-100. 
Lysate containing 25 µg protein was assayed for chymotrypsin activity utilising the 
fluorogenic substrate N-Succinyl-Ala-Ala-Pro-Phe-AMC, final concentration 50 µM. 
Significant differences are denoted by *. 
 
Figure 2.   HeLa (A) and U251 mg (B) cells were incubated with 100 Μm TMR-Phe-
DPP for various timepoints before being harvested and lysed in sterile PBS containing 
0.1% (v/v) TX-100. Lysates containing 25 µg protein were assayed for caspase-3 
activation utilising the fluorogenic substrate Ac-DEVD-AMC, final concentration 25 
µM.  No significant difference was found between control and treated cells within 
each timepoint between 30 min and 3 hours.  A significant difference (*) was 
observed 6 and 4 hrs, respectively with a highly significant (***) difference observed 
at 12 hrs for U251 mg cells (p<0.0001).   
 
Figure 3.  HeLa (A) and U251 mg (B) cells were incubated with 100 µM TMR-Phe-
DPP, for various timepoints between 30 minutes and 24 hours. Cells were then 
harvested and lysed with PBS containing 0.1% (v/v) TX-100. PARP cleavage was 
detected in samples (25 µg protein) by immunodetection utilising an anti-PARP 
antibody (1:500) and a goat anti-mouse HRP conjugate (1:10,000). Arrows represent 
the uncleaved (116 kDa) and cleaved (85 kDa) PARP species. 
 
Figure 4.  HeLa cells were incubated with 100 µM TMR-Phe-DPP, for various 
timepoints: (A) 1 hr; (B) 3 hr; (C) 4 hr and (D) 6 hr, before staining with Annexin V-
Cy5 Apoptosis Detection Kit according to the manufacturer’s instructions. All images 
are at x200 magnification. 
 
Figure 5.  Phase contrast and fluorescent overlay images of HeLa cells following 
incubation with 100 µM TMR-Phe-DPP: (A) 30 min; (B) 1 hr; (C) 4 hr and (D) 8 hr. 
The inhibitor was observed to localise in the cytosol within 30 minutes. At 4 hours 
post incubation, morphological changes indicative of apoptosis were apparent 
(Magnification x200). 
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Figure 6.  Confocal microscopy images of U251 mg cells following 1 hour incubation 
with 100 µM TMR-Phe-DPP. Cells were grown on coverslips before the addition of 
the inhibitor. Following 1 hour, cells were washed and mounted onto microscope 
slides. Images show cytosolic location of the peptide (A) x2500 and (B) x4000 
magnification.  (C) 1 µM  peptide; x7000 magnification. 
Figure 7.  A. Intact HeLa cells were incubated at 37oC, with 5% CO2 for 24 hours 
with 100 µM TMR-Phe-DPP and 100 µM BPS-Phe-DPP. Cells were lysed before 
undergoing SDS-PAGE. UV light highlighted a fluorescent band of approximately 58 
kDa in lane 1, which contained the lysate and TMR-Phe-DPP.  Lanes: (M) markers; 
(C) untreated control cells; (1) HeLa cells + TMR-Phe-DPP and (2) HeLa cells + 
BPS-Phe-DPP. The fluorescence at the bottom of lane three is attributed to ‘wash-
through’ of the fluorogenic probe. B. Intact HeLa cells were incubated at 37°C for 30 
min with (1) control (no probe); (2) Bio-Phe-DPP (not thought to be cell permeable); 
(3) TMR-Phe-DPP (cell permeable) and (4) Z-Phe-DPP (cell permeable).  Cells were 
then lysed and the lysate subjected to a secondary incubation with 100 µM Biotin-
Phe-DPP. The samples were then subjected to SDS-PAGE and Western Blotting with 
visualisation using streptavidin-HRP (1:5000). 
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Table 1.   
HeLa cells were incubated for 24 hours at 37oC with 100 µM of chymotrypsin-like proteinase inhibitors.  Cell 
viability was assessed using standard MTT assay and presented as % cell viability of control  
 
Inhibitor Cell viability 
(% control) 
p-value 
Z-Phe-DPP 67% 0.0002*** 
EDANS-Phe-DPP 73% 0.0006*** 
BPS-Phe-DPP 94% 0.1957 
TMR-Phe-DPP 16% <0.0001*** 
TPCK 79% 0.0181* 
Tosyl-Phe-DPP 71% <0.0001*** 
Z-Phe-DPP: Benzyloxycarbonyl-phenylalanyl-diphenylphosphate; EDANS: 5-[(2-
aminoethyl)amino]naphthalene-1-sulfonic acid; BPS: Biotin-PEG-Succinyl; TMR: 
Tetramethylrhodamine and TPCK: N-α-tosyl-L-phenylalanine chloromethylketone.  
 
